BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue British Journal of Haematology Année : 2021

BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres

Résumé

No abstract available

Domaines

Cancer

Dates et versions

inserm-03349131 , version 1 (20-09-2021)

Identifiants

Citer

Hervé Ghesquières, Cécile Dalban, Emmanuelle Nicolas‐virelizier, Fabrice Jardin, Fabien Le Bras, et al.. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres. British Journal of Haematology, 2021, 192 (3), pp.e94-e98. ⟨10.1111/bjh.17279⟩. ⟨inserm-03349131⟩
34 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More